Evidence of alveolar macrophage metabolic shift following SBRT-induced lung fibrosis in mice.

Lung Macrophage Pneumonitis fibrosis focal irradiation mice radiation

Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
13 Sep 2024
Historique:
received: 12 02 2024
revised: 22 08 2024
accepted: 04 09 2024
medline: 16 9 2024
pubmed: 16 9 2024
entrez: 15 9 2024
Statut: aheadofprint

Résumé

Radiation-induced pneumopathy is the main dose-limiting factor in cases of chest radiation therapy. Macrophage infiltration is frequently observed in irradiated lung tissues and may participate in lung damage development. Radiation-induced lung fibrosis can be reproduced in rodent models using whole thorax irradiation but suffers from limits concerning the role played by unexposed lung volumes in damage development. Here we used an accurate Stereotactic Body Radiation Therapy (SBRT) preclinical model irradiating 4% of the mouse lung. Tissue damage development and macrophages populations were followed by histology, flow cytometry and single cell RNA sequencing. Wild type and CCR2 KO mice in which monocytes recruitment is abrogated, were exposed to single doses of radiations inducing progressive (60 Gy) or rapid (80 Gy) lung fibrosis. Numerous clusters of macrophages were observed around the injured area, during progressive as well as rapid fibrosis. Results indicate that probably CCR2-independent recruitment and/or in situ proliferation may be responsible for macrophage invasion. Alveolar macrophages experience a metabolic shift from fatty acid metabolism to cholesterol biosynthesis, directing them through a possible pro-fibrosing phenotype. Depicted data revealed that the origin and phenotype of macrophages present to the injured area may differ from what has been previously described in preclinical models exposing large lung volumes, representing a potentially interesting trail in the deciphering of radiation-induced lung damage processes. Our study brings new possible clues to the understanding of macrophage implication in radiation-induced lung damage, representing an interesting area for exploration in future studies.

Sections du résumé

BACKGROUND BACKGROUND
Radiation-induced pneumopathy is the main dose-limiting factor in cases of chest radiation therapy. Macrophage infiltration is frequently observed in irradiated lung tissues and may participate in lung damage development. Radiation-induced lung fibrosis can be reproduced in rodent models using whole thorax irradiation but suffers from limits concerning the role played by unexposed lung volumes in damage development.
METHODS METHODS
Here we used an accurate Stereotactic Body Radiation Therapy (SBRT) preclinical model irradiating 4% of the mouse lung. Tissue damage development and macrophages populations were followed by histology, flow cytometry and single cell RNA sequencing. Wild type and CCR2 KO mice in which monocytes recruitment is abrogated, were exposed to single doses of radiations inducing progressive (60 Gy) or rapid (80 Gy) lung fibrosis.
RESULTS RESULTS
Numerous clusters of macrophages were observed around the injured area, during progressive as well as rapid fibrosis. Results indicate that probably CCR2-independent recruitment and/or in situ proliferation may be responsible for macrophage invasion. Alveolar macrophages experience a metabolic shift from fatty acid metabolism to cholesterol biosynthesis, directing them through a possible pro-fibrosing phenotype. Depicted data revealed that the origin and phenotype of macrophages present to the injured area may differ from what has been previously described in preclinical models exposing large lung volumes, representing a potentially interesting trail in the deciphering of radiation-induced lung damage processes.
CONCLUSION CONCLUSIONS
Our study brings new possible clues to the understanding of macrophage implication in radiation-induced lung damage, representing an interesting area for exploration in future studies.

Identifiants

pubmed: 39278419
pii: S0360-3016(24)03391-1
doi: 10.1016/j.ijrobp.2024.09.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest none

Auteurs

Sarah Braga-Cohen (S)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Jérémy Lavigne (J)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Morgane Dos Santos (MD)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRAcc, F-92260, Fontenay-aux-Roses, France.

Georges Tarlet (G)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Valérie Buard (V)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Jan Baijer (J)

Plateforme de cytométrie, UMR « Stabilité Génétique, Cellules souches et Radiations », CEA-INSERM-Universités de Paris et Paris-Sud, CEA-DRF/JACOB/iRCM/UMRE008-U1274, BP6 92265, Fontenay-aux-Roses Cedex, France.

Olivier Guipaud (O)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Vincent Paget (V)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Eric Deutsch (E)

INSERM U1030, Gustave Roussy, Université Paris-Saclay, 94 800, Villejuif, France; Département d'Oncologie Radiothérapie, Gustave Roussy, 94 800, Villejuif, France.

Mohamed Amine Benadjaoud (MA)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED, F-92260, Fontenay-aux-Roses, France.

Michele Mondini (M)

INSERM U1030, Gustave Roussy, Université Paris-Saclay, 94 800, Villejuif, France.

Fabien Milliat (F)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France.

Agnès François (A)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SERAMED/LRMed, F-92260, Fontenay-aux-Roses, France. Electronic address: agnes.francois@irsn.fr.

Classifications MeSH